This clustered Project Performance Assessment Report (PPAR) chapeau report synthesizes evaluation findings from six International Finance Corporation (IFC) investment projects in the pharmaceutical and life sciences sector, specifically targeting generic prescription drugs and consumer health products across five countries in three regions. The projects were selected for PPAR through purposeful sampling in consultation with IFC’s Global Health team and regional industry departments. These projects were committed during FY 2017–18 and selected based on the achievement of early operating maturity.

The clustered PPAR chapeau report addresses the following topics: 

• The efficacy of IFC’s investments in improving the accessibility, quality, and affordability of critical pharmaceuticals and life sciences products.

• Management of environmental and social (E&S) risks in these projects and their effect on environmental and social sustainability. 

• Key internal and external factors that enabled or constrained IFC’s effectiveness in the projects. 

• IFC’s additionality (that is, the benefit or value addition that IFC brings that a client would not otherwise have; additionality can be financial or nonfinancial) in projects beyond financing (for example, knowledge transfer, advisory services, World Bank Group collaboration, and E&S sustainability). 

• Lessons learned and their implications, which can be applied across the pharma value chain, particularly in developing markets, to resolve supply-side constraints.